{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:49:17Z","timestamp":1774313357680,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:11:45Z","timestamp":1743635505000},"page":"443.e1-443.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to bacillus Calmette-Gu\u00e9rin and gemcitabine-docetaxel therapy"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-6058","authenticated-orcid":false,"given":"Ahmed","family":"Eraky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik P.","family":"Kolanukuduru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Hug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyrollis","family":"Attalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Waingankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2025.03.009_bib0001","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of nonmuscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.03.009_bib0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.urolonc.2025.03.009_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.009_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk non-muscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.03.009_bib0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/his.14764","article-title":"What's new in WHO fifth edition\u2009-\u2009urinary tract","volume":"81","author":"Comp\u00e9rat","year":"2022","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.009_bib0007","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00345-020-03180-5","article-title":"Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up","volume":"39","author":"Mariappan","year":"2021","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.009_bib0008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non\u2013muscle-invasive bladder cancer: a multicenter European Association of Urology non\u2013muscle-invasive bladder cancer Guidelines panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2024.09.006","article-title":"Comparative Effectiveness of Bacillus Calmette-Gu\u00e9rin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-na\u00efve Intermediate-risk Non-muscle-invasive Bladder Cancer","author":"Kolanukuduru","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical Bacillus Calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0013","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Sylvester","year":"2022","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.urolonc.2025.03.009_bib0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical Gemcitabine and Docetaxel is an alternative to Bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.009_bib0016","first-page":"485.e1","article-title":"Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer","volume":"41","author":"McElree","year":"2023"},{"issue":"3","key":"10.1016\/j.urolonc.2025.03.009_bib0017","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00345-024-04992-5","article-title":"Induction and maintenance of sequential intravesical gemcitabine\/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols","volume":"42","author":"Ben-David","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.03.009_bib0019","series-title":"Urologic oncology: multidisciplinary care for patients","first-page":"313","article-title":"Evolving treatment in non-muscle-invasive bladder cancer","author":"Eilender","year":"2022"},{"key":"10.1016\/j.urolonc.2025.03.009_bib0020","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2438291","article-title":"Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer","volume":"14","author":"Ca\u00f1izo","year":"2025","journal-title":"OncoImmunology"},{"issue":"12","key":"10.1016\/j.urolonc.2025.03.009_bib0022","doi-asserted-by":"crossref","first-page":"485.e1","DOI":"10.1016\/j.urolonc.2023.06.017","article-title":"Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer","volume":"41","author":"McElree","year":"2023","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.009_bib0023","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR inhibition in urothelial carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.03.009_bib0024","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncology"},{"issue":"14","key":"10.1016\/j.urolonc.2025.03.009_bib0025","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.3390\/jcm13144112","article-title":"Contemporary treatment of NMIBC\u2014Is it time to move on from BCG?","volume":"13","author":"Passarelli","year":"2024","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.03.009_bib0026","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.009_bib0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Gu\u00e9rin\u2012na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.009_bib0028","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13193-018-0728-8","article-title":"Low-grade, multiple, Ta non-muscle-invasive bladder tumors: tumor recurrence and worsening progression","volume":"9","author":"Nerli","year":"2018","journal-title":"Indian J Surg Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.03.009_bib0029","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/cncr.33300","article-title":"Predicting risk of multiple levels of recurrence and progression after initial diagnosis of non-muscle-invasive bladder cancer in a multisite, community-based cohort","volume":"127","author":"Garg","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.03.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design","author":"Matulay","year":"2021","journal-title":"J Urol"},{"issue":"35","key":"10.1016\/j.urolonc.2025.03.009_bib0031","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for Bladder Cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2025.03.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non\u2013muscle-invasive Bladder Cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a Multicenter Young Academic Urologists Urothelial Working Group collaboration","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:42:52Z","timestamp":1748443372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392500105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S107814392500105X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to bacillus Calmette-Gu\u00e9rin and gemcitabine-docetaxel therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}